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230 Comparison of three methods to measure body composition in
patients with cystic ﬁbrosis. Relation with retrotricipital skinfold
thickness and brachial circumference
M. Beaumesnil, C. Bonnemains, A. Hoppe´1, E. Darviot, J.L. Ginie`s. Centre de
Ressources et de Compe´tence pour la Mucoviscidose, CHU, Angers, France
Fifty-ﬁve patients with cystic ﬁbrosis, 27 girls and 28 boys, participated in this study.
The mean age was 14±5 years at the time of the examination and the age range
was 4 to 29 years. Four skinfolds and the brachial circumference were measured
in all patients, and the percentage of fat mass and muscle circumference were
calculated. Fifty patients underwent dual energy X-ray absorptiometry (Hologic®
QDR 4500) and 38 underwent bioelectric impedance measurements (Bodystat®
QuadScan 4000).
The relationship between fat mass (FM) and lean body mass (LBM) was highly
signiﬁcant as calculated by the three methods: for LBM, r = 0.98 to 0.99, and for FM,
r = 0.81 to 0.95, depending on the pair of measures used (p< 0.001). Anthropom-
etry overestimated LBM by 8±4% compared with absorptiometry and by 6±7%
compared with impedance measurement. Impedance measurement overestimated it
by 4±6% (p< 0.001) compared with absorptiometry. High correlations were also
found between the anthropometric, absorptiometric and impedance measurements
of LBM and the muscle circumference (r = 0.86, r = 0.83 and r = 0.84, p< 0.001)
and FM and the retrotricipital skinfold thickness (r = 0.76, r = 0.75 and r = 0.60,
p< 0.001).
Measuring retrotricipital skinfold thickness and brachial circumference and cal-
culating the muscle circumference are rapid and simple methods to evaluate body
composition during clinical consultation. The excellent correlation between the three
methods of measuring body composition validates all of them for use in patients
with cystic ﬁbrosis but the results were not identical and each should be interpreted
in terms of its own references values.
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Adiponectin is an adipocytokine with anti-inﬂammatory and insulin-sensitizing
properties. Adiponectin is low in obesity and high in conditions with energy deﬁcit.
Objective: To evaluate adiponectin concentration in CF patients and correlate it
with body composition.
Subjects: 18 stable CF patients [mean age (±SD): 14.97±5.82 yrs] and 18 healthy
controls, matched for body mass index (BMI), age and sex.
Methods: Bioelectrical Impedance Analysis [%Body Fat (%BF) and %Lean Mass
(%LM)], CT-scan at the L3-L4 level for visceral adipose tissue (VAT) measurement
(CF patients). HOMA-IR for insulin resistance (IR) and serum adiponectin (ELISA,
R&D-Systems) were measured.
Results: Although weight and height were signiﬁcantly lower in CF patients than
controls (p< 0.05), BMI and %BF were comparable. HOMA-IR was also compara-
ble. CF males were signiﬁcantly taller (p = 0.038) than females. Absolute and %LM
were signiﬁcantly higher in CF males and %BF in females (p< 0.001). Adiponectin
was higher in CF patients than controls (12.07±6.56 vs. 10.67±4.4mg/ml) and
in CF females as compared to CF males (13.83±7.85 vs. 10.31±4.77mg/ml)not
statistically signiﬁcant). Adiponectin was signiﬁcantly higher in pre-pubertal CF
patients in comparison to pubertal (14.82±8.01 vs. 8.18±1.85mg/ml, p = 0.040)
and comparable to CF adults (10.52±3.72mg/ml). Adiponectin correlated with %BF
(r = 0.507, p = 0.044) but was not affected by the amount or percentage of VAT.
Conclusion: CF patients have higher serum adiponectin than healthy controls. This
may be attributed to the energy deﬁcit inherent to the disease.
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Introduction: Cystic Fibrosis patients have been reported to have delayed growth and
onset of puberty.
Aim: The aim of this study was to assess the pubertal status in a group of CF patients
in relation to their age.
Patients and Methods: In 19 patients (9M) ranging in age from 7 to 19 years,
Shwachman Score (SS), body mass index (BMI) and % body fat (%BF) were evaluated.
Gonadotropin (FSH, LH), sex hormones (estrogens, testosterone) and DHEA’S were
measured.
Results: The results are shown in the table. No correlation was found with BMI-SDS,
%BF and SS.
Conclusions: Although the onset of puberty in these patients was found to be within
the acceptable age range of 8 to 14 years, it occurred at the latest normal limit.
Furthermore, approximately one third of the patients had low hormone secretion for
their corresponding age as compared to the reference values.
Patient hormone values-1
Age/Gender 7M 7F 9F 9F 9M 10F 12M 13F 15F
FSH 1.31 2.7 3.59 5.49 0.48 4.75 0.22 1.83 5.93
LH 0.12 <0.1 0.14 0.14 <0.1 0.33 <0.1 0.16 1.06
E2 <20 <20 <20 <20 <20 24.7 <20 <20 23.4
TESTO <20 <20 <20 <20 <20 <20 <20 <20 62.5
DHEA’s 18.9 17.4 18 16.8 <15 22.1 45.4 <15 57.6
Patient hormone values-2
Age/Gender 15M 15F 15M 16M 16F 17M 17M 18F 18F 19M
FSH 1.96 6.43 6.94 1.83 6.84 5.91 1.04 8.59 5.35 3.35
LH 1.41 6.73 6.63 0.53 4.93 5.37 0.3 39.5 3.26 3.05
E2 32.7 <20 <20 <20 25.9 27.6 <20 116 36 24.4
TESTO 585 66 1151 302 57 752 213 <20 44 441
DHEA’s 67.1 162 – 182 98 352 56.3 103 67.3 340
233 Carotenoid supplementation in CF – How to ﬁnd a way to do it
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Intake of carotenoids is under discussion since b-carotene (BC) failed in clinical
efﬁcacy trials. Nevertheless, there is still a need for carotenoids in CF. BC supple-
mentation in CF patients led to improved FEV1 and a lower need of antibiotics.
Recently, Schupp et al. reported lutein deﬁciency in plasma and a decreased macular
pigment in CF patients. This might be of relevance in older CF patients since an
earlier development of age-related macular degeneration might occur.
Smokers on increased dosages of BC in the intervention trials showed a higher
mortality because of lung cancer and cardiovascular complications. As shown by
our group these effects might be related to oxidative BC breakdown products (BP)
leading to inhibition of enzymes, to mitochondrial damage, and to genotoxic effects.
However, BCBP will develop only when high BC tissue concentrations are reached
and increased oxidative stress is present. CF patients showing a high degree of
inﬂammation in their lung tissue might possibly be on a similar risk.
However, due to malabsorption of lipids increased BC tissue concentrations can
hardly be reached in CF and, in addition, a careful monitoring of plasma levels
should avoid overdosing. Furthermore, maintenance of sufﬁcient levels of other
antioxidants should protect carotenoids in vivo. On the other hand, in vitro studies
showed that secondary antioxidants in cells, such as the 20S-proteasome, are able
to degrade proteins oxidized by BCBP, but only to a certain extent. In conclusion,
safe conditions for carotenoid supplementation in CF patients can be reached and,
therefore, a new approach of regular supplementation of carotenoids should be
discussed
